What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class II recall affecting a specific batch of prescription medication distributed across the United States. This action involves Carbamazepine Tablets, USP, which are prescribed at a strength of 200mg. The product is packaged in large, 1000-count bottles intended for retail or institutional dispensing, and it carries the "Rx only" designation, meaning it is available strictly by prescription from a licensed healthcare provider. While the brand name associated with this recall notice is Sun Pharmaceutical Industries, the manufacturing record indicates that the tablets were actually produced by Taro Pharmaceutical Industries Ltd., located in Haifa Bay, Israel. The distribution was handled by Taro Pharmaceuticals USA, Inc., based in Hawthorne, New York.
To identify the affected inventory, you must look closely at the National Drug Code (NDC) and lot information on the bottle label. The specific product identified in this recall carries the NDC number 51672-4005-3. The critical identifier for consumers is the Lot Number AD94033. This particular lot has an expiration date of May 31, 2028. It is important to note that the recall is limited strictly to this lot number; bottles with different lot numbers or expiration dates are not part of this specific safety notice, even if they share the same NDC and packaging style.
The scope of this distribution was nationwide, meaning these bottles could have been sold in pharmacies, hospitals, or clinics in all 50 states. The recall was officially initiated on August 3, 2026. Although the FDA classification is Class II, which typically indicates a situation where use of the product may cause temporary or medically reversible adverse health consequences, the widespread distribution pattern means that patients across the country who were prescribed this medication during the relevant time frame need to verify their supply immediately. The recall does not currently list any specific incidents of injury, but the presence of manufacturing deviations necessitates this precautionary measure for anyone holding stock with Lot # AD94033.
If you have a bottle of Carbamazepine Tablets, USP 200mg in a 1000-count container, do not assume it is safe without checking the lot number printed on the label. The manufacturer and distributor information must match Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals USA, Inc., respectively. If your bottle matches these details exactly and bears Lot # AD94033, it is part of this recall. If the lot number differs, or if the NDC ends in a different suffix, your medication is likely unaffected by this specific FDA action. Always consult the physical packaging for the most accurate identification, as generic substitutions or different package sizes may carry different codes.
The hazard, explained
When you pick up a bottle of prescription medication, you expect every tablet inside to be identical in appearance, composition, and potency. This consistency is not just about aesthetics; it is the foundation of safe medical treatment. In this specific recall involving Carbamazepine tablets manufactured by Taro Pharmaceutical Industries Ltd. and distributed under the Sun Pharmaceutical Industries brand, that fundamental expectation has been compromised due to Critical Good Manufacturing Practice (CGMP) deviations. Specifically, the issue stems from a physical defect in the manufacturing process: black spots have been found on the surface of the tablets. These are not merely cosmetic blemishes; they indicate that the chemical integrity of the pill was disrupted during production.
To understand why this matters, it helps to look at how these tablets are made. Carbamazepine is a complex drug used to treat seizures and nerve pain. The active ingredient must be evenly distributed throughout a matrix of inactive ingredients, known as excipients, which help the pill hold its shape and dissolve properly in your body. During the mixing or compression phase of manufacturing, something went wrong that caused portions of these excipients to burn. This "burnt" material creates the visible black spots you might see on the surface of the tablets. Think of it like baking a cake where part of the batter scorched; while the rest might look fine, the chemical structure of that scorched portion has fundamentally changed.
The primary danger here lies in what happens when you ingest a tablet with these burnt excipient spots. First and foremost is the risk of inconsistent dosing. If a significant portion of the tablet's mass consists of degraded or altered material, the actual amount of active carbamazepine available for your body to absorb may be lower than labeled. For a drug like Carbamazepine, which requires precise levels in your bloodstream to prevent seizures or manage pain, even a small reduction in potency can be clinically significant. You might take what you believe is a full dose, but receive less, potentially leading to breakthrough symptoms or loss of disease control.
Furthermore, the degradation of excipients can alter how the tablet breaks down in your stomach and intestines. Burnt or charred materials may dissolve at a different rate than intended, leading to unpredictable absorption times. This unpredictability is particularly risky for medications with a narrow therapeutic index, where the difference between a helpful dose and an ineffective one is slim. While the FDA has classified this as a Class II recall—indicating that use of the product might cause temporary or medically reversible health consequences—the uncertainty introduced by these physical defects means you cannot rely on the bottle to provide the safe, consistent treatment your doctor prescribed. Ignoring the physical signs of manufacturing failure can inadvertently turn a life-saving medication into an unreliable one.
Who is most at risk
To understand who faces the greatest potential concern in this recall, we first need to look at the nature of the medication itself. Carbamazepine is a prescription drug primarily used to treat epilepsy, trigeminal neuralgia (a chronic pain condition affecting the face), and bipolar disorder. It is not an over-the-counter remedy; it is a powerful chemical agent that requires careful management by a healthcare provider. Because the product involved in this FDA recall is specifically distributed in 1000-count bottles, it indicates that the affected units were likely dispensed to long-term patients or filled for extended therapy regimens. Therefore, the primary group at potential risk consists of individuals who have been prescribed Carbamazepine by a licensed physician and have received their medication from Taro Pharmaceuticals USA, Inc. These are people who rely on this specific dosage, 200mg, to maintain stability in their health conditions.
The specific hazard identified in this recall involves Good Manufacturing Practice (CGMP) deviations, resulting in black spots found on the tablets due to burnt excipient during manufacturing. While the FDA has classified this as a Class II recall—meaning it is not expected to cause serious adverse health consequences or death—it does not mean the risk is negligible for everyone involved. The primary vulnerability here stems from the unpredictability of the medication's integrity. For patients with seizure disorders like epilepsy, consistency in drug delivery is critical. Even though the black spots are described as burnt excipient (inactive ingredients that help bind the pill) rather than a change in the active carbamazepine ingredient, any physical anomaly in a controlled-release or immediate-release tablet can raise valid concerns about how the drug dissolves and absorbs in the body. If the structural integrity of the pill is compromised by these manufacturing errors, it could theoretically lead to uneven absorption, potentially causing fluctuations in blood levels of the drug.
Certain populations may feel this disruption more acutely than others. Elderly patients, who often take multiple medications and may have reduced metabolic efficiency, are particularly sensitive to changes in how their body processes drugs. For older adults managing bipolar disorder or chronic nerve pain, even minor variations in medication efficacy can trigger a return of symptoms that were previously under control. Furthermore, individuals who have experienced severe side effects from previous batches of medications might experience heightened anxiety or physical distress upon noticing the black spots, which could indirectly affect their well-being through stress responses. While the recall notice does not report any actual incidents of injury, the potential for risk is highest among those who are dependent on the precise chemical stability of this drug to manage serious neurological or psychiatric conditions.
It is also important to note that because the distribution was nationwide, any patient in New Jersey or elsewhere in the U.S. who received Lot # AD94033 with an expiration date of May 31, 2028, from a pharmacy that stocks Taro Pharmaceuticals products could be affected. The risk is not limited to those who take the pill daily; it extends to anyone who has this bottle in their home medicine cabinet, as they may inadvertently use it if they do not check the lot number. For these individuals, the immediate risk is not necessarily toxicity from the black spots themselves, but rather the uncertainty of treatment efficacy and the potential for psychological distress caused by a compromised medical product.
How to tell if you have the recalled item
Knowing exactly what you are holding is the first step in protecting your health during a medication recall. Because this recall involves a specific batch of prescription drugs, visual inspection alone may not be enough. You need to look for precise identifiers on the packaging and the individual blister packs or bottles. The U.S. Food and Drug Administration (FDA) has issued this notice because of quality control issues during manufacturing, specifically regarding burnt excipients that caused black spots on the tablets. Therefore, checking both the outer container and the physical appearance of the pill is essential.
Start by locating the bottle or box your medication came in. You are looking for a product distributed by Taro Pharmaceuticals USA, Inc., based in Hawthorne, NY. The manufacturer listed on the label is Taro Pharmaceutical Industries Ltd., located in Haifa Bay, Israel. Confirm that the drug name matches exactly: Carbamazepine Tablets, USP, 200mg. This is a prescription-only medication, so it should have been dispensed by a pharmacy with a valid Rx label attached.
The most critical piece of information to verify is the National Drug Code (NDC) and the Lot Number. The recalled product carries the NDC number 51672-4005-3. This code identifies the specific product line and packaging size. In this case, the recall applies specifically to bottles containing 1000 tablets. If you have a smaller bottle or a different NDC, it is likely not part of this recall, but always double-check with your pharmacist.
Next, find the Lot Number printed on the label. The specific lot subject to this recall is AD94033. Locate the expiration date as well; the recalled tablets expire on May 31, 2028. If your bottle has a different lot number or expiration date, it is not part of this specific recall action. Keep the bottle handy when you contact your healthcare provider or pharmacist.
If you have already opened the bottle, inspect the tablets themselves. The hazard in this recall involves CGMP (Current Good Manufacturing Practice) deviations that resulted in black spots on the tablets due to burnt excipient during the manufacturing process. Look closely at each tablet for any unusual dark specks or discoloration that does not match the standard appearance of Carbamazepine 200mg tablets. If you see black spots, do not take the medication. Even if the lot number matches but the pills look normal, it is still safest to return them for professional disposal and replacement, as internal quality issues may not always be visible.
This recall affects products distributed nationwide across the United States, including New Jersey. If you purchased these tablets from any pharmacy or healthcare provider in the U.S., there is a possibility your medication is included. Do not rely on memory or store location alone; the lot number and NDC are your definitive guides.
- Product Name: Carbamazepine Tablets, USP, 200mg
- Packaging: 1000 count bottles (Rx only)
- Distributor: Taro Pharmaceuticals USA, Inc.
- NDC: 51672-4005-3
- Lot Number: AD94033
- Expiration Date: 5/31/2028
What to do — step by step
When you encounter a recall notice for a prescription medication, the immediate instinct might be to panic or simply toss the bottle in the trash. However, handling this situation with care is crucial for your safety and for ensuring the manufacturer can effectively address the quality control issue. Because this specific recall by Sun Pharmaceutical Industries Inc., involving Carbamazepine Tablets manufactured by Taro Pharmaceutical Industries Ltd., has not yet stated a formal remedy or return procedure in the official FDA announcement, your actions must focus on immediate cessation of use and professional medical guidance rather than a direct consumer refund process.
- Stop taking the medication immediately. The primary hazard here involves CGMP (Current Good Manufacturing Practice) deviations, specifically the presence of black spots on the tablets caused by burnt excipient during the manufacturing process. While the exact clinical impact of these particulates is not detailed in the current report, any foreign material in a drug intended for long-term management of conditions like epilepsy or nerve pain poses an unacceptable risk. Do not wait for symptoms to appear; discontinue use right away if you have the affected product.
- Contact your prescribing physician without delay. This is the most critical step. Carbamazepine is a potent medication often used to control seizures and treat certain mental disorders or nerve pain. Stopping it abruptly can lead to serious health consequences, including seizure recurrence or withdrawal effects. Call your doctor’s office today. Explain that you possess the recalled lot (AD94033) of the 200mg tablets distributed nationwide. Your doctor will determine the safest way to transition you to a different manufacturer or dosage form. They may provide a new prescription for a safe alternative, ensuring there is no gap in your treatment.
- Securely store the recalled product. Do not flush the pills down the toilet or throw them loosely into household trash where they might be retrieved by others or pets. Place the bottle in a sealed bag or container to prevent accidental access. Keep the bottle intact so that the NDC (51672-4005-3) and lot number remain visible for your records.
- Await further instructions from regulatory bodies. Since the official FDA recall announcement does not currently list a specific return address or refund mechanism, monitor updates on the FDA website or contact Taro Pharmaceuticals USA, Inc. directly for future guidance. If a return program is announced later, follow those specific instructions precisely. For now, your priority is medical continuity and safe storage.
Your refund, repair, or replacement options
When you receive news about a medication recall, the immediate concern is often how to handle the product itself and what financial recourse is available. In this specific instance involving Sun Pharmaceutical Industries Inc. and its distributor, Taro Pharmaceuticals USA, Inc., the official FDA recall announcement dated August 3, 2026, provides a critical piece of information that requires careful attention: the remedy for this recall has not been explicitly stated in the current public record.
This does not mean you are left without guidance, but it does mean that standard procedures for refunds or replacements may differ from typical recalls where a clear "return for credit" instruction is provided. Because the FDA classification is Class II, indicating that use of the product could cause temporary or medically reversible serious injury, the priority is safety first. You should not attempt to sell, donate, or continue using these tablets. The absence of a specified remedy in the initial notice suggests that the distribution pattern and identification of the affected lot are the primary tools for containment at this stage.
To determine your specific options, you must contact the entities responsible for the product's journey to your pharmacy. The recall involves Carbamazepine Tablets, USP, 200mg, manufactured by Taro Pharmaceutical Industries Ltd. in Israel and distributed by Taro Pharmaceuticals USA, Inc. in Hawthorne, NY. Your first step should be to reach out to the pharmacy where you filled your prescription. Pharmacists are trained to handle recall notifications and often have direct lines to the distributor’s customer service or quality assurance teams. They can inform you if a replacement of the exact same drug is available from a non-recalled lot, or if they can coordinate a return process with Taro Pharmaceuticals USA, Inc.
If you purchased the product directly or need to contact the manufacturer for clarification on potential refunds or replacements, you should look for the customer service contact information listed on the packaging or through Taro Pharmaceuticals USA, Inc.’s official corporate channels. Since the recall notice does not list a specific phone number or website for consumer inquiries, your pharmacy is the most reliable intermediary. They can advise whether they will accept the return of the 1000-count bottles (NDC 51672-4005-3, Lot # AD94033) and process any associated credits or refunds according to their internal policies for recalled goods.
In the meantime, do not discard the medication in your household trash or flush it down the toilet unless instructed to do so by a healthcare professional or local waste disposal authority. Proper disposal is part of the safety protocol. Keep the bottle and its label handy, as you will need the lot number (AD94033) and expiration date (5/31/2028) when speaking with any representative. This information is essential for verifying that your specific batch is indeed part of this recall. Until a formal remedy is announced by the FDA or communicated by Taro Pharmaceuticals, your primary action is to secure alternative treatment from your doctor if necessary and to cooperate with your pharmacy’s return instructions.
What can happen if you ignore it
When you receive a notification that your medication has been recalled due to manufacturing defects, it is natural to feel frustrated or even anxious about the logistics of replacing it. However, continuing to use the affected product is not just an inconvenience; it is a significant health risk that requires immediate attention. In this specific case involving Sun Pharmaceutical Industries’ Carbamazepine tablets, the core issue is not that the drug has stopped working entirely, but that its physical integrity and purity have been compromised during production. Ignoring this recall means exposing yourself to particulate matter that should never be ingested, which can lead to unpredictable physiological reactions.
The primary hazard identified in this recall is the presence of black spots on the tablets, caused by burnt excipients—inactive ingredients used to bind the drug together—during the manufacturing process. While Carbamazepine is a critical medication often prescribed for epilepsy and nerve pain, consistency in dosage is vital. The presence of these burnt particles suggests that the uniform distribution of the active ingredient may be irregular across different tablets within the same bottle. This means you might inadvertently receive a tablet with a higher concentration of the drug than intended, or conversely, one with less. For a medication with a narrow therapeutic index, where small changes in dosage can have large effects on your body, this inconsistency is dangerous. It can lead to breakthrough seizures if the dose is too low, or severe toxicity and side effects if the dose is unexpectedly high.
Beyond dosage inconsistency, ingesting burnt organic material poses its own set of risks. Excipients are generally recognized as safe when processed correctly, but charring or burning them alters their chemical structure. Ingesting these altered compounds can irritate the gastrointestinal tract, potentially causing nausea, abdominal pain, or other digestive distress that complicates your ability to monitor your actual medical condition. More seriously, if the burnt material contains unknown degradation products, there is a theoretical risk of allergic reactions or toxic responses that are not part of the standard side effect profile of Carbamazepine. Your body may react unpredictably to these foreign substances, leading to symptoms that could be mistaken for an adverse reaction to the drug itself, thereby confusing your healthcare provider’s ability to manage your treatment effectively.
Furthermore, ignoring a Class II recall undermines the safety net designed to protect public health. The FDA classifies this as a Class II recall because it is likely to cause temporary or medically reversible serious injury, or where the probability of serious injury is remote. However, "remote" does not mean "impossible." By continuing to take these tablets, you are gambling with your neurological stability and overall well-being for no benefit. The consequences range from manageable physical discomfort to severe medical crises that require emergency intervention. There is no upside to waiting; the risk of harm increases every day you continue to consume a product that has failed quality control standards.
It is also important to consider the impact on your broader healthcare management. If you experience unexpected symptoms while taking recalled medication, your doctor may misattribute these issues to progression of your underlying condition or other medications you are taking. This can lead to unnecessary changes in your treatment plan, adding new drugs with their own side effects when the real culprit was the defective product. Clearing the air by returning the recalled items and obtaining fresh, tested medication ensures that your healthcare team has an accurate picture of your health status, free from the variable of contaminated supply.
Finally, there is a subtle but important ethical and systemic consideration. When individuals ignore recalls, it can delay the manufacturer’s ability to understand the full scope of the defect. This prolongs the time during which other patients might be exposed to the same risk. By acting promptly, you not only protect yourself but also contribute to the rapid resolution of the safety issue, helping to ensure that the corrective actions taken by Taro Pharmaceutical Industries and Sun Pharmaceutical Industries are effective for everyone involved. Your immediate compliance helps close the loop on this safety concern, reducing the likelihood of future incidents.
Staying safe: broader tips
While this specific recall highlights a manufacturing irregularity involving visual defects in prescription medication, it serves as a valuable reminder of the broader importance of vigilance when managing your health and home safety. Pharmaceutical products are subject to rigorous Good Manufacturing Practice (GMP) standards, but unexpected issues can occasionally arise during production. The most effective way to stay protected is to establish simple, consistent habits that keep you informed and proactive. One of the best steps you can take is to register your medications with the manufacturer or sign up for FDA safety alerts. These notifications ensure that you are among the first to know if a batch of any drug you use is pulled from the market due to safety concerns, allowing you to act quickly rather than reactively.
When it comes to prescription drugs, never hesitate to inspect your medications upon receipt and before taking them. Look for changes in color, texture, or the presence of unusual spots or particles that were not present when the bottle was sealed. If a pill looks different from what you are used to, or if the packaging seems compromised, set it aside and contact your pharmacist immediately. Pharmacists are highly trained professionals who can verify lot numbers against current recall databases and help determine whether your specific supply is affected. This simple visual check can provide peace of mind and prevent potential health risks associated with contaminated or improperly manufactured products.
Beyond medications, consider creating a routine for checking all household items for recalls. Many consumer products, from car seats to kitchen appliances, have known safety issues that are addressed through voluntary recalls managed by agencies like the Consumer Product Safety Commission (CPSC) or the National Highway Traffic Safety Administration (NHTSA). You can subscribe to email alerts from these agencies to receive regular updates on new recalls relevant to your home. Additionally, keep a record of major purchases, including serial numbers and purchase dates, in a dedicated folder or digital file. This organization makes it much easier to identify if you own a recalled item and facilitates the process of returning or repairing the product.
Finally, foster an open dialogue with your healthcare providers about any concerns you have regarding your medications. If you notice unexpected side effects or have questions about the source of your prescriptions, your doctor or pharmacist can provide guidance tailored to your specific health needs. By staying engaged in your health management and keeping informed about safety updates, you empower yourself to make safer choices and reduce the likelihood of encountering issues like the one described in this recall. Remember that prevention is always easier than remediation, and small habits of awareness can go a long way in protecting your well-being.